[go: up one dir, main page]

EE200200549A - Jagatud doosi teraapia veresooni kahjustava aktiivsusega - Google Patents

Jagatud doosi teraapia veresooni kahjustava aktiivsusega

Info

Publication number
EE200200549A
EE200200549A EEP200200549A EEP200200549A EE200200549A EE 200200549 A EE200200549 A EE 200200549A EE P200200549 A EEP200200549 A EE P200200549A EE P200200549 A EEP200200549 A EE P200200549A EE 200200549 A EE200200549 A EE 200200549A
Authority
EE
Estonia
Prior art keywords
vascular damaging
dose therapy
split dose
damaging activity
damaging agent
Prior art date
Application number
EEP200200549A
Other languages
English (en)
Inventor
David Davis Peter
Original Assignee
Angiogene Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007740A external-priority patent/GB0007740D0/en
Priority claimed from GB0013928A external-priority patent/GB0013928D0/en
Priority claimed from GB0014904A external-priority patent/GB0014904D0/en
Application filed by Angiogene Pharmaceuticals Ltd. filed Critical Angiogene Pharmaceuticals Ltd.
Publication of EE200200549A publication Critical patent/EE200200549A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EEP200200549A 2000-03-31 2001-03-27 Jagatud doosi teraapia veresooni kahjustava aktiivsusega EE200200549A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0007740A GB0007740D0 (en) 2000-03-31 2000-03-31 Combination therapy
GB0013928A GB0013928D0 (en) 2000-06-08 2000-06-08 Methods of treatment
GB0014904A GB0014904D0 (en) 2000-06-20 2000-06-20 Methods of treatment
PCT/GB2001/001329 WO2001074369A1 (en) 2000-03-31 2001-03-27 Divided dose therapies with vascular damaging activity

Publications (1)

Publication Number Publication Date
EE200200549A true EE200200549A (et) 2004-02-16

Family

ID=27255635

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200549A EE200200549A (et) 2000-03-31 2001-03-27 Jagatud doosi teraapia veresooni kahjustava aktiivsusega

Country Status (23)

Country Link
US (1) US20030055024A1 (et)
EP (1) EP1272200B1 (et)
JP (1) JP2003528921A (et)
KR (1) KR20020084267A (et)
CN (1) CN1422157A (et)
AT (1) ATE298240T1 (et)
AU (2) AU2001242586B2 (et)
BR (1) BR0109671A (et)
CA (1) CA2402078A1 (et)
CZ (1) CZ20023231A3 (et)
DE (1) DE60111622T2 (et)
EE (1) EE200200549A (et)
ES (1) ES2243466T3 (et)
HU (1) HUP0300576A3 (et)
IL (1) IL151627A0 (et)
IS (1) IS6555A (et)
MX (1) MXPA02009603A (et)
NO (1) NO20024683L (et)
NZ (1) NZ534190A (et)
PL (1) PL357282A1 (et)
PT (1) PT1272200E (et)
SK (1) SK13902002A3 (et)
WO (1) WO2001074369A1 (et)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (fr) * 2002-12-06 2006-10-27 Aventis Pharma Sa Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
US20060142239A1 (en) * 2003-06-18 2006-06-29 Ryan Anderson J Potassium or sodium salt of (-)-2-(4-hydroxyphenyl)ethyl!-thio-3-'4-{4-'(methzlsulfonzl)oxy !phenoxy}phenyl!propanoic acid and their use in medicine
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67646A0 (en) * 1982-01-15 1983-05-15 Lilly Co Eli Ascorbic acid ethers and related compounds
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
WO1991006668A1 (en) * 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
DK0526488T3 (da) * 1990-04-02 1995-04-24 Pfizer Benzylphosphonsyre-tyrosinkinaseinhibitorer
CA2108889A1 (en) * 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH11228594A (ja) * 1998-02-16 1999-08-24 Meiji Milk Prod Co Ltd 新規プロゲステロン化合物
ATE324888T1 (de) * 1999-06-14 2006-06-15 Cancer Rec Tech Ltd Krebstherapie
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent

Also Published As

Publication number Publication date
MXPA02009603A (es) 2004-05-14
SK13902002A3 (sk) 2003-05-02
AU2001242586B2 (en) 2004-12-16
PT1272200E (pt) 2005-09-30
AU4258601A (en) 2001-10-15
ES2243466T3 (es) 2005-12-01
NZ534190A (en) 2007-05-31
KR20020084267A (ko) 2002-11-04
IL151627A0 (en) 2003-04-10
JP2003528921A (ja) 2003-09-30
EP1272200B1 (en) 2005-06-22
PL357282A1 (en) 2004-07-26
CA2402078A1 (en) 2001-10-11
DE60111622D1 (de) 2005-07-28
DE60111622T2 (de) 2006-05-18
HUP0300576A3 (en) 2005-02-28
EP1272200A1 (en) 2003-01-08
NO20024683D0 (no) 2002-09-30
IS6555A (is) 2002-10-18
WO2001074369A1 (en) 2001-10-11
US20030055024A1 (en) 2003-03-20
NO20024683L (no) 2002-10-15
CZ20023231A3 (cs) 2003-01-15
ATE298240T1 (de) 2005-07-15
HUP0300576A2 (hu) 2003-07-28
BR0109671A (pt) 2003-02-04
CN1422157A (zh) 2003-06-04

Similar Documents

Publication Publication Date Title
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
PT1223980E (pt) Utilizacao de inibidores de csf-1
GB0223380D0 (en) Combination therapy
IL189546A0 (en) Therapy for the treatment of disease
BRPI0412426A (pt) uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente
NO20032027D0 (no) Effektive antitumorbehandlinger
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
BRPI0412450A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular em um animal de sangue quente tal como um ser humano, e para o tratamento de um cáncer, composição farmacêutica, kit, e, uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd6126 ou um sal farmaceuticamente aceitável deste
NO20043774L (no) The use of devazenide as analgesic agent
DE60308403D1 (de) Kombinationstherapie mit gemzitabin und zd6126
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
RU2003110183A (ru) Способ лечения рассеянного склероза